Clinical Data Warehouse : definitions and use cases
Prof. Stéfan Darmoni, France, discusses the clinical data warehouses (CDW) where he explains its definitions and various use cases.
Video Clinical Data Warehouse : definitions and use cases -Copyright ©2022 by PanNash™ Initiative - All rights reserved.
Prof. Stéfan Darmoni, France, makes a detailed explanation on Hospital Information System and discusses the HDW objectives while reviewing the HDW objectives in clinical research. Prof. Stéfan, then makes a detailed review on the CDW state of the art where he discusses various tools such as ehop, Dr Warehouse, ConSoRe, and EDSaN. For the clinicians, he presents the big data derived from the Rouen University Hospital Clinical Data Warehouse and makes a demo on the EDSaN platform and discusses some of the use cases.
- Prof. Stéfan Darmoni
- March 23, 2022
- More Definition, Management
Would you like to read more?
Prof. Stéfan Darmoni
International NASH Day 2023: Empowering Healthcare Professionals
On International NASH Day 2023, PanNASH amplifies the importance of NASH awareness, education, and action. Learn about the complex multisystem…
Nordic NASH Symposium
PanNASH speaker; Dr. Stephen Harrison takes part in the Nordic NASH symposium which aims to discuss management and diagnosis strategies…
The role of circadian clocks in the pathogenesis of NAFLD
The circadian clock controls rhythms responsible for regulating bodily functions, e.g., appropriate eating times. When this clock becomes disrupted due…
Hepatocellular carcinoma surveillance in NAFLD patients
Nonalcoholic fatty liver disease (NAFLD) is characterised by the presence of hepatic steatosis without significant alcohol consumption or concomitant liver…
MAFLD and inflammatory bowel disease: a prospective cohort study
MAFLD and inflammatory bowel disease: a prospective cohort study
Coffee achieves its beneficial effects through modulation of insulin resistance in a NAFLD mouse model
Coffee achieves its beneficial effects through modulation of insulin resistance in a NAFLD mouse model
B cells aggravate NASH: an innate and adaptive signalling
In this study, F. Barrow et al. (University of Minnesota Medical School, Minneapolis, USA) report that NASH livers accumulate B…
NAFLD: from drivers to targets
In this review, A. Santos-Laso et al. (Marqués de Valdecilla University Hospital, Valdecilla Biomedical Research Institute, Santander, Spain) summarise the…
NASH: an Overview Through 200 Years of Clinical Research
Although the term 'fatty liver hepatitis' first appeared in 1962, it was in 1980 that the term 'non-alcoholic steatohepatitis' (NASH)…
Immune cell-mediated features of NASH
In this review, T. Huby and E. L. Gautier (Sorbonne Université, Hôpital de la Pitié-Salpêtrière, Paris, France) discuss “current concepts…
Steatohepatitis: hypothesis for a pathomechanism
In this article, P. M. Abuja et al. (Medical University of Graz, Austria) propose that steatohepatitis develops in four phases…
Fatty liver through the ages: Nonalcoholic steatohepatitis
In this article, Z. M. Younossi et al. (Inova Health System, Falls Church, VA, USA) aimed to review the current…
SUBSCRIBE & FOLLOW US
Subscribe Our Newsletter To Get the Lastest Updates
